Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects

In previous studies, a dichotomous stratification of subjects into "cerebrospinal fluid (CSF) normal" and "CSF pathologic" was used to investigate the role of biomarkers in the prediction of progression to dementia in pre-dementia/mild cognitive impairment subjects. With the prev...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of Alzheimer's disease Ročník 48; číslo 2; s. 433 - 441
Hlavní autori: Lewczuk, Piotr, Kornhuber, Johannes, Toledo, Jon B, Trojanowski, John Q, Knapik-Czajka, Malgorzata, Peters, Oliver, Wiltfang, Jens, Shaw, Leslie M
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands 01.01.2015
Predmet:
Aged
Aged, 80 and over
Algorithms
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - diagnosis
Amyloid beta-Peptides - cerebrospinal fluid
Asymptomatic Diseases
Biomarkers - cerebrospinal fluid
Disease Progression
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Longitudinal Studies
Middle Aged
Peptide Fragments - cerebrospinal fluid
Phosphorylation
Prognosis
Proportional Hazards Models
tau Proteins - cerebrospinal fluid
Alzheimer’s disease
clinical neurochemistry
biomarkers
validation
cerebrospinal fluid
results interpretation
ISSN:1875-8908
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:In previous studies, a dichotomous stratification of subjects into "cerebrospinal fluid (CSF) normal" and "CSF pathologic" was used to investigate the role of biomarkers in the prediction of progression to dementia in pre-dementia/mild cognitive impairment subjects. With the previously published Erlangen Score Algorithm, we suggested a division of CSF patterns into five groups, covering all possible CSF result combinations based on the presence of pathologic tau and/or amyloid-β CSF values. This study aimed to validate the Erlangen Score diagnostic algorithm based on the results of biomarkers analyses obtained in different patients cohorts, with different pre-analytical protocols, and with different laboratory analytical platforms. We evaluated the algorithm in two cohorts of pre-dementia subjects: the US-Alzheimer's Disease Neuroimaging Initiative and the German Dementia Competence Network. In both cohorts, the Erlangen scores were strongly associated with progression to Alzheimer's disease. Neither the scores of the progressors nor the scores of the non-progressors differed significantly between the two projects, in spite of significant differences in the cohorts, laboratory methods, and the samples treatment. Our findings confirm the utility of the Erlangen Score algorithm as a useful tool in the early neurochemical diagnosis of Alzheimer's disease.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1875-8908
DOI:10.3233/JAD-150342